Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of TDO2 as a potential therapeutic target

doi:10.4330/wjc.v15.i6.293

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3845)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-1) series.

Item

Count

PDF

105

WORD

HTML

1727

Figures (1-8)

276

Tables (1-1)

236

Sum=2386

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

128

Download

604

Sum=732

Publishing Process of This Article

Item

Count

Browse

130

Download

435

Sum=565

Jun 26, 2023 (publication date) through Dec 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Cardiol. Jun 26, 2023; 15(6): 293-308
Published online Jun 26, 2023. doi: 10.4330/wjc.v15.i6.293

Full Size Figure Download Figure

Figure 4 Survival analysis of overlapping hub genes. Overall survival curves show that higher expression of TDO2, HSD17B6, SULF1, SDR16C5, COL3A1, KCNMA1, KCNMB4, KCNN4 and ALADH1A3 is associated with a worse survival rate. A: TDO2; B: HSD17B6; C: SULF1; D: SDR16C5; E: COL3A1; F: KCNMA1; G: KCNMB4; H: KCNN4; I: ALADH1A3.

Citation: Wang R, Yang YM. Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of TDO2 as a potential therapeutic target. World J Cardiol 2023; 15(6): 293-308
URL: https://www.wjgnet.com/1949-8462/full/v15/i6/293.htm
DOI: https://dx.doi.org/10.4330/wjc.v15.i6.293